首页> 外文期刊>British journal of ophthalmology >Evolution of therapies for the corneal endothelium: past, present and future approaches
【24h】

Evolution of therapies for the corneal endothelium: past, present and future approaches

机译:角膜内皮疗法的演变:过去,现在和未来的方法

获取原文
获取原文并翻译 | 示例
       

摘要

Corneal endothelial diseases are leading indications for corneal transplantations. With significant advancement in medical science and surgical techniques, corneal transplant surgeries are now increasingly effective at restoring vision in patients with corneal diseases. In the last 15 years, the introduction of endothelial keratoplasty (EK) procedures, where diseased corneal endothelium (CE) are selectively replaced, has significantly transformed the field of corneal transplantation. Compared to traditional penetrating keratoplasty, EK procedures, namely Descemet’s stripping automated endothelial keratoplasty (DSAEK) and Descemet membrane endothelial keratoplasty (DMEK), offer faster visual recovery, lower immunological rejection rates, and improved graft survival. Although these modern techniques can achieve high success, there are fundamental impediments to conventional transplantations. A lack of suitable donor corneas worldwide restricts the number of transplants that can be performed. Other barriers include the need for specialized expertise, high cost, and risks of graft rejection or failure. Research is underway to develop alternative treatments for corneal endothelial diseases, which are less dependent on the availability of allogeneic tissues – regenerative medicine and cell-based therapies. In this review, an overview of past and present transplantation procedures used to treat corneal endothelial diseases are described. Potential novel therapies that may be translated into clinical practice will also be presented.
机译:角膜内皮疾病是角膜移植的主要迹象。由于医学科学和手术技术的显着进步,角膜移植手术现在越来越有效地恢复角膜疾病患者的视野。在过去的15年中,引入内皮角膜或ek)程序,其中患病的角膜内皮(Ce)被选择性更换,显着改变了角膜移植领域。与传统的穿透性角膜形成术相比,EK程序,即Descemet的剥离自动内皮角膜术(Dsaek)和Descemet膜内皮角膜或达到型号),提供更快的视觉回收率,降低免疫抑制率和改进的移植物存活。虽然这些现代技术可以实现高成功,但传统移植有基本的障碍。缺乏合适的捐助玉米体全球限制可以进行的移植器的数量。其他障碍包括需要专业专业知识,高成本和接枝抑制或失败的风险。正在进行研究以开发角膜内皮疾病的替代治疗,这不太依赖于同种异体组织 - 再生医学和基于细胞的疗法的可用性。在本文中,描述了过去和目前移植程序的概述,用于治疗角膜内皮疾病。还将呈现可能转化为临床实践的潜在新疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号